thursday, october 29 | 10:00 AM ET
Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Featured Key Opinion Leaders
Firas Rahhal, MD
Partner, Retina-Vitreous Associates Medical Group
Dr. Firas M. Rahhal received a Bachelor’s degree in Biochemistry from the University of Pennsylvania, then received his MD from the University of Connecticut School of Medicine. He completed an Ophthalmology Residency at Cornell University Medical Center in New York City and subsequently a two-year fellowship in vitreoretinal surgery and uveitis at the University of California, San Diego Medical Center. After fellowship, Dr. Rahhal returned to Cornell University as Assistant Professor of Ophthalmology and was appointed the Director of the Retina Service, staying in that position for five years.
Dr. Rahhal is currently a partner at Retina-Vitreous Associates Medical Group in Los Angeles and is an Associate Clinical Professor of Ophthalmology at the UCLA School of Medicine – Jules Stein Eye Institute. He is an extremely busy and respected clinician and clinical researcher. He has published dozens of scientific papers in reputable peer-reviewed journals and is a frequent presenter at major international scientific meetings. He has been an investigator in over 100 clinical trials, many of which were national or international trials leading to novel therapies for vitreoretinal diseases. Among numerous other awards, Dr. Rahhal has been consistently named “Top Doctor” by his physician peers in the Los Angeles Magazine annual review. He is Board Certified by the American Board of Ophthalmology, and is a member of the American Academy of Ophthalmology, the American Society of Retina Specialists, and The Retina Society. He is Co-Director of the RVA-USC Joint Vitreoretinal Fellowship training program.
Lawrence A. Kenyon
President, Chief Executive Officer and Chief Financial Officer
Mr. Kenyon has served as our President and CEO and as a member of our board of directors since August 2018. He has also served as our Chief Financial Officer and Secretary since September 2015. Prior to that, from February 2014 to September 2015, Mr. Kenyon served as the Chief Financial Officer of Arno Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics for cancer and other life threatening diseases, and also as Chief Operating Officer from July 2014 to September 2015. From December 2011 to March 2013, Mr. Kenyon served as the Interim President & Chief Executive Officer, Chief Financial Officer and Secretary of Tamir Biotechnology, Inc., a publicly held biopharmaceutical company engaged in the development of oncology and anti-infective therapeutics.
Chief Operating Officer
Mr. Dagnon has served as our Chief Operating Officer since November 2018. He was most recently Senior Vice President of Operations at Dohmen Life Science Services. Terry’s 20 years of regulatory experience has involved responsibility from research to post-market with a large number of domestic and global investigational and marketing approvals in the pharmaceutical and medical device industries. He is also experienced in quality and compliance and working with R&D, Marketing, Sales, Legal, and Manufacturing, Quality and Supply Chain organizations. Terry began his career in the pharmaceutical industry as the Regulatory Affairs Manager for Physician Reliance Network Inc. (now known as U.S. Oncology). He continued his regulatory affairs career at Johnson & Johnson Medical Inc. with global regulatory responsibility for the Wound Care, Skin Care and Tissue Engineering franchises. He then served as the North America Head of Regulatory Affairs at Alcon a Novartis company prior to joining DLSS in March 2014. At Dohmen Life Science Services he was responsible for all operational activities at the Denver site and in running the following service lines servicing Pharmaceutical, Biologics, MedTech, and Rare industry segments: QA/RA/Safety/Medical Affairs/CMC/Project Management Consulting and Quality Management System Outsourcing.
Chief Commercial Officer
Mr. Evanson has served as our Chief Commercial Officer since November 2018. Mr. Evanson joined Outlook Therapeutics from Scott Three Consulting where he was the Founder and President. Previously he was a Managing Director in the Life Science Practice of Navigant from 2014 to 2018. He joined the firm in September of 2014 from Novartis (Alcon) where he was the Vice President and Global Commercial Head of the Pharmaceutical Franchise. During his time at Alcon, he was responsible for all aspects of strategy, portfolio (both internal and external opportunities), global brands, launches and campaigns. Mr. Evanson has extensive experience with the ophthalmology and retina landscape including sustained delivery, drug/device combination and diagnostics within the dry eye, glaucoma, retina and allergy eye health markets.